← Back to Search

Protease Inhibitor

Ecallantide for Hereditary Angioedema

Phase 2
Waitlist Available
Led By Mark A Davis-Lorton, MD
Research Sponsored by Mark Davis-Lorton, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

The objective of this study is to evaluate the safety and tolerability of a single Subcutaneous (SC) dose of Ecallantide in children and adolescents with Hereditary Angioedema (HAE).

Eligible Conditions
  • Hereditary Angioedema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measurement of time to symptomatic improvement from acute attacks of hereditary angioedema
Secondary outcome measures
Number of Partcipants with Adverse Events

Side effects data

From 2007 Phase 3 trial • 91 Patients • NCT00262080
11%
Headache
8%
Hereditary Angioedema
8%
Pyrexia
8%
Diarrhoea
6%
Tachycardia
6%
Nasal Congestion
6%
Nasopharyngitis
3%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Double-Blind Placebo
Double Blind - Ecallantide
Repeat-Dosing Ecallantide

Trial Design

1Treatment groups
Experimental Treatment
Group I: EcallantideExperimental Treatment1 Intervention
Study Medication, Dose, and Mode of Administration: Single dose of ecallantide subcutaneous dosing: Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg. Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg.

Find a Location

Who is running the clinical trial?

Mark Davis-Lorton, MDLead Sponsor
NYU Langone HealthLead Sponsor
1,369 Previous Clinical Trials
840,598 Total Patients Enrolled
Dyax Corp.Industry Sponsor
3 Previous Clinical Trials
207 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
Mark Davis-Lorton, MD 2013. "Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01832896.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top